Recombinant TNFSF11 (Denosumab Biosimilar) antibody
Quick Overview for Recombinant TNFSF11 (Denosumab Biosimilar) antibody (ABIN7200656)
Target
Antibody Type
Fragment
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Purpose
- Denosumab Biosimilar, Human RANKL Monoclonal Antibody
-
Specificity
- The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
-
Characteristics
- Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Sterility
- 0.2 μm filtered
-
Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.
-
Isotype
- IgG2
-
-
-
-
Application Notes
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
-
Preservative
- Without preservative
-
Storage
- 4°C,-20 °C
-
Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
-
Expiry Date
- 12 months
-
-
- TNFSF11 (Denosumab Biosimilar)
-
Alternative Name
- Denosumab Biosimilar
-
Target Type
- Biosimilar
Target
-